Header Logo

Connection

Stuart Levitz to Cryptococcus neoformans

Back to Details
This is a "connection" page, showing publications Stuart Levitz has written about Cryptococcus neoformans.
Stuart Levitz
Connection Strength
13.975
Cryptococcus neoformans
  1. Specht CA, Wang R, Oliveira LVN, Hester MM, Gomez C, Mou Z, Carlson D, Lee CK, Hole CR, Lam WC, Upadhya R, Lodge JK, Levitz SM. Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans, vaccine deficient in chitosan. mBio. 2024 Aug 14; 15(8):e0174624.
    View in: PubMed
    Score: 0.813
  2. Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLoS Pathog. 2024 Jul; 20(7):e1012220.
    View in: PubMed
    Score: 0.813
  3. Hester MM, Oliveira LVN, Wang R, Mou Z, Lourenco D, Ostroff GR, Specht CA, Levitz SM. Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis. Front Immunol. 2022; 13:1015586.
    View in: PubMed
    Score: 0.719
  4. Specht CA, Homan EJ, Lee CK, Mou Z, Gomez CL, Hester MM, Abraham A, Rus F, Ostroff GR, Levitz SM. Protection of Mice against Experimental Cryptococcosis by Synthesized Peptides Delivered in Glucan Particles. mBio. 2021 02 22; 13(1):e0336721.
    View in: PubMed
    Score: 0.643
  5. Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P, Abraham A, Shen ZT, Lodge JK, Akalin A, Homan J, Ostroff GR, Levitz SM. Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017 11 28; 8(6).
    View in: PubMed
    Score: 0.514
  6. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. mBio. 2015 Dec 22; 6(6):e01905-15.
    View in: PubMed
    Score: 0.449
  7. Wang JP, Lee CK, Akalin A, Finberg RW, Levitz SM. Contributions of the MyD88-dependent receptors IL-18R, IL-1R, and TLR9 to host defenses following pulmonary challenge with Cryptococcus neoformans. PLoS One. 2011; 6(10):e26232.
    View in: PubMed
    Score: 0.337
  8. Mansour MK, Vyas JM, Levitz SM. Dynamic virulence: real-time assessment of intracellular pathogenesis links Cryptococcus neoformans phenotype with clinical outcome. mBio. 2011; 2(5).
    View in: PubMed
    Score: 0.335
  9. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect Immun. 2008 Oct; 76(10):4764-71.
    View in: PubMed
    Score: 0.269
  10. Dan JM, Wang JP, Lee CK, Levitz SM. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One. 2008 Apr 30; 3(4):e2046.
    View in: PubMed
    Score: 0.265
  11. Dan JM, Kelly RM, Lee CK, Levitz SM. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect Immun. 2008 Jun; 76(6):2362-7.
    View in: PubMed
    Score: 0.263
  12. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis. 2007 Sep 01; 196(5):796-800.
    View in: PubMed
    Score: 0.251
  13. Yauch LE, Lam JS, Levitz SM. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2006 Nov; 2(11):e120.
    View in: PubMed
    Score: 0.239
  14. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect Immun. 2006 Jul; 74(7):3817-24.
    View in: PubMed
    Score: 0.233
  15. Levitz SM, Specht CA. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res. 2006 Jun; 6(4):513-24.
    View in: PubMed
    Score: 0.232
  16. Mansour MK, Latz E, Levitz SM. Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J Immunol. 2006 Mar 01; 176(5):3053-61.
    View in: PubMed
    Score: 0.228
  17. Yauch LE, Mansour MK, Levitz SM. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun. 2005 Dec; 73(12):8429-32.
    View in: PubMed
    Score: 0.224
  18. Kelly RM, Chen J, Yauch LE, Levitz SM. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun. 2005 Jan; 73(1):592-8.
    View in: PubMed
    Score: 0.210
  19. Yauch LE, Mansour MK, Shoham S, Rottman JB, Levitz SM. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. Infect Immun. 2004 Sep; 72(9):5373-82.
    View in: PubMed
    Score: 0.205
  20. Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun. 2004 Mar; 72(3):1746-54.
    View in: PubMed
    Score: 0.198
  21. Hester MM, Carlson D, Lodge JK, Levitz SM, Specht CA. Immune evasion by Cryptococcus gattii in vaccinated mice coinfected with C. neoformans. Front Immunol. 2024; 15:1356651.
    View in: PubMed
    Score: 0.198
  22. Specht CA, Lam WC, Hester MM, Lourenco D, Levitz SM, Lodge JK, Upadhya R. Chitosan-Deficient Cryptococcus as Whole-Cell Vaccines. Methods Mol Biol. 2024; 2775:393-410.
    View in: PubMed
    Score: 0.196
  23. Sephton-Clark P, McConnell SA, Grossman N, Baker RP, Dragotakes Q, Fan Y, Fu MS, Gerbig G, Greengo S, Hardwick JM, Kulkarni M, Levitz SM, Nosanchuk JD, Shoham S, Smith DFQ, Stempinski P, Timp W, Wear MP, Cuomo CA, Casadevall A. Similar evolutionary trajectories in an environmental Cryptococcus neoformans isolate after human and murine infection. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2217111120.
    View in: PubMed
    Score: 0.183
  24. Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM. Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses. Infect Immun. 2002 Oct; 70(10):5485-93.
    View in: PubMed
    Score: 0.180
  25. Harrison TS, Chen J, Simons E, Levitz SM. Determination of the pH of the Cryptococcus neoformans vacuole. Med Mycol. 2002 Jun; 40(3):329-32.
    View in: PubMed
    Score: 0.176
  26. Mansour MK, Schlesinger LS, Levitz SM. Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J Immunol. 2002 Mar 15; 168(6):2872-9.
    View in: PubMed
    Score: 0.173
  27. Levitz SM. Receptor-mediated recognition of Cryptococcus neoformans. Nihon Ishinkin Gakkai Zasshi. 2002; 43(3):133-6.
    View in: PubMed
    Score: 0.171
  28. Levitz SM. Does amoeboid reasoning explain the evolution and maintenance of virulence factors in Cryptococcus neoformans? Proc Natl Acad Sci U S A. 2001 Dec 18; 98(26):14760-2.
    View in: PubMed
    Score: 0.170
  29. Levitz SM. Cryptococcus neoformans: intracellular or extracellular? Trends Microbiol. 2001 Sep; 9(9):417-8.
    View in: PubMed
    Score: 0.167
  30. Levitz SM, Nong S, Mansour MK, Huang C, Specht CA. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc Natl Acad Sci U S A. 2001 Aug 28; 98(18):10422-7.
    View in: PubMed
    Score: 0.166
  31. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001 Apr 01; 166(7):4620-6.
    View in: PubMed
    Score: 0.162
  32. Weber SM, Levitz SM. Chloroquine antagonizes the proinflammatory cytokine response to opportunistic fungi by alkalizing the fungal phagolysosome. J Infect Dis. 2001 Mar 15; 183(6):935-42.
    View in: PubMed
    Score: 0.161
  33. Mambula SS, Simons ER, Hastey R, Selsted ME, Levitz SM. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect Immun. 2000 Nov; 68(11):6257-64.
    View in: PubMed
    Score: 0.157
  34. Harrison TS, Griffin GE, Levitz SM. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans. J Infect Dis. 2000 Jul; 182(1):283-9.
    View in: PubMed
    Score: 0.154
  35. Huang C, Levitz SM. Stimulation of macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta, and RANTES by Candida albicans and Cryptococcus neoformans in peripheral blood mononuclear cells from persons with and without human immunodeficiency virus infection. J Infect Dis. 2000 Feb; 181(2):791-4.
    View in: PubMed
    Score: 0.149
  36. Kwon-Chung KJ, Sorrell TC, Dromer F, Fung E, Levitz SM. Cryptococcosis: clinical and biological aspects. Med Mycol. 2000; 38 Suppl 1:205-13.
    View in: PubMed
    Score: 0.149
  37. Hester MM, Lee CK, Abraham A, Khoshkenar P, Ostroff GR, Levitz SM, Specht CA. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2020 01 16; 38(3):620-626.
    View in: PubMed
    Score: 0.147
  38. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, Simons ER. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun. 1999 Feb; 67(2):885-90.
    View in: PubMed
    Score: 0.139
  39. Teitz-Tennenbaum S, Viglianti SP, Roussey JA, Levitz SM, Olszewski MA, Osterholzer JJ. Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection. J Immunol. 2018 10 01; 201(7):2004-2015.
    View in: PubMed
    Score: 0.135
  40. Levitz SM, Harrison TS, Tabuni A, Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest. 1997 Sep 15; 100(6):1640-6.
    View in: PubMed
    Score: 0.127
  41. Harrison TS, Nong S, Levitz SM. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J Infect Dis. 1997 Aug; 176(2):485-91.
    View in: PubMed
    Score: 0.126
  42. Harrison TS, Levitz SM. Mechanisms of impaired anticryptococcal activity of monocytes from donors infected with human immunodeficiency virus. J Infect Dis. 1997 Aug; 176(2):537-40.
    View in: PubMed
    Score: 0.126
  43. Levitz SM, North EA. Lymphoproliferation and cytokine profiles in human peripheral blood mononuclear cells stimulated by Cryptococcus neoformans. J Med Vet Mycol. 1997 Jul-Aug; 35(4):229-36.
    View in: PubMed
    Score: 0.125
  44. Levitz SM, North EA, Jiang Y, Nong SH, Kornfeld H, Harrison TS. Variables affecting production of monocyte chemotactic factor 1 from human leukocytes stimulated with Cryptococcus neoformans. Infect Immun. 1997 Mar; 65(3):903-8.
    View in: PubMed
    Score: 0.122
  45. Levitz SM, Tabuni A, Kozel TR, MacGill RS, Ingalls RR, Golenbock DT. Binding of Cryptococcus neoformans to heterologously expressed human complement receptors. Infect Immun. 1997 Mar; 65(3):931-5.
    View in: PubMed
    Score: 0.122
  46. Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev. 1996 Oct; 9(4):469-88.
    View in: PubMed
    Score: 0.119
  47. Kozel TR, Tabuni A, Young BJ, Levitz SM. Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun. 1996 Jun; 64(6):2336-8.
    View in: PubMed
    Score: 0.116
  48. Upadhya R, Lam WC, Maybruck B, Specht CA, Levitz SM, Lodge JK. Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans. mBio. 2016 05 10; 7(3).
    View in: PubMed
    Score: 0.115
  49. Levitz SM, North EA. gamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicans. Infect Immun. 1996 May; 64(5):1595-9.
    View in: PubMed
    Score: 0.115
  50. Levitz SM, Tabuni A, Nong SH, Golenbock DT. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect Immun. 1996 Mar; 64(3):945-51.
    View in: PubMed
    Score: 0.114
  51. Levitz SM, North EA, Dupont MP, Harrison TS. Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes. Infect Immun. 1995 Sep; 63(9):3550-4.
    View in: PubMed
    Score: 0.110
  52. Harrison TS, Kornfeld H, Levitz SM. The effect of infection with human immunodeficiency virus on the anticryptococcal activity of lymphocytes and monocytes. J Infect Dis. 1995 Sep; 172(3):665-71.
    View in: PubMed
    Score: 0.110
  53. Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, Komori M, Blake A, Browne SK, Rosen LB, Hagen F, Meis J, Levitz SM, Quezado M, Hammoud D, Bennett JE, Bielekova B, Williamson PR. Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathog. 2015 May; 11(5):e1004884.
    View in: PubMed
    Score: 0.108
  54. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun. 1994 May; 62(5):1975-81.
    View in: PubMed
    Score: 0.100
  55. Levitz SM. Macrophage-Cryptococcus interactions. Immunol Ser. 1994; 60:533-43.
    View in: PubMed
    Score: 0.098
  56. Levitz SM, Dupont MP, Smail EH. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun. 1994 Jan; 62(1):194-202.
    View in: PubMed
    Score: 0.098
  57. Levitz SM, Tabuni A, Treseler C. Effect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes. Infect Immun. 1993 Nov; 61(11):4891-3.
    View in: PubMed
    Score: 0.097
  58. Roseff SA, Levitz SM. Effect of endothelial cells on phagocyte-mediated anticryptococcal activity. Infect Immun. 1993 Sep; 61(9):3818-24.
    View in: PubMed
    Score: 0.096
  59. Levitz SM, Dupont MP. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest. 1993 Apr; 91(4):1490-8.
    View in: PubMed
    Score: 0.093
  60. Levitz SM, Tabuni A, Wagner R, Kornfeld H, Smail EH. Binding of unopsonized Cryptococcus neoformans by human bronchoalveolar macrophages: inhibition by a large-molecular-size serum component. J Infect Dis. 1992 Oct; 166(4):866-73.
    View in: PubMed
    Score: 0.090
  61. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991 Nov-Dec; 13(6):1163-9.
    View in: PubMed
    Score: 0.084
  62. Levitz SM. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun. 1991 Oct; 59(10):3393-7.
    View in: PubMed
    Score: 0.084
  63. Levitz SM, Farrell TP, Maziarz RT. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J Infect Dis. 1991 May; 163(5):1108-13.
    View in: PubMed
    Score: 0.081
  64. Levitz SM, Tabuni A. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J Clin Invest. 1991 Feb; 87(2):528-35.
    View in: PubMed
    Score: 0.080
  65. Jesus MD, Nicola AM, Chow SK, Lee IR, Nong S, Specht CA, Levitz SM, Casadevall A. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence. 2010 Nov-Dec; 1(6):500-8.
    View in: PubMed
    Score: 0.079
  66. Levitz SM, Farrell TP. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect Immun. 1990 May; 58(5):1201-9.
    View in: PubMed
    Score: 0.076
  67. Levitz SM, DiBenedetto DJ. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol. 1989 Jan 15; 142(2):659-65.
    View in: PubMed
    Score: 0.069
  68. Wozniak KL, Levitz SM. Isolation and purification of antigenic components of Cryptococcus. Methods Mol Biol. 2009; 470:71-83.
    View in: PubMed
    Score: 0.069
  69. Levitz SM, DiBenedetto DJ. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect Immun. 1988 Oct; 56(10):2544-51.
    View in: PubMed
    Score: 0.068
  70. Banks IR, Specht CA, Donlin MJ, Gerik KJ, Levitz SM, Lodge JK. A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans. Eukaryot Cell. 2005 Nov; 4(11):1902-12.
    View in: PubMed
    Score: 0.056
  71. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol. 2005 Jun; 129(5):569-82.
    View in: PubMed
    Score: 0.054
  72. Kozel TR, Levitz SM, Dromer F, Gates MA, Thorkildson P, Janbon G. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun. 2003 May; 71(5):2868-75.
    View in: PubMed
    Score: 0.047
  73. Ieong MH, Reardon CC, Levitz SM, Kornfeld H. Human immunodeficiency virus type 1 infection of alveolar macrophages impairs their innate fungicidal activity. Am J Respir Crit Care Med. 2000 Sep; 162(3 Pt 1):966-70.
    View in: PubMed
    Score: 0.039
  74. Weber SM, Levitz SM, Harrison TS. Chloroquine and the fungal phagosome. Curr Opin Microbiol. 2000 Aug; 3(4):349-53.
    View in: PubMed
    Score: 0.039
  75. Parayath KE, Harrison TS, Levitz SM. Effect of interleukin (IL)-15 priming on IL-12 and interferon-gamma production by pathogen-stimulated peripheral blood mononuclear cells from human immunodeficiency virus-seropositive and -seronegative donors. J Infect Dis. 2000 Feb; 181(2):733-6.
    View in: PubMed
    Score: 0.037
  76. Harrison TS, Levitz SM. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection. J Immunol. 1996 Jun 01; 156(11):4492-7.
    View in: PubMed
    Score: 0.029
  77. Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, Lee CG, Elias JA, Nielsen JN, Boulware DR, Bohjanen PR, Jenkins MK, Levitz SM, Nielsen K. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog. 2015 Mar; 11(3):e1004701.
    View in: PubMed
    Score: 0.027
  78. Wagner RP, Levitz SM, Tabuni A, Kornfeld H. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. Am Rev Respir Dis. 1992 Dec; 146(6):1434-8.
    View in: PubMed
    Score: 0.023
  79. Levitz SM, DiBenedetto DJ, Diamond RD. Inhibition and killing of fungi by the polyamine oxidase-polyamine system. Antifungal activity of the PAO-polyamine system. Antonie Van Leeuwenhoek. 1990 Aug; 58(2):107-14.
    View in: PubMed
    Score: 0.019
  80. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med. 2000 Feb 01; 132(3):205-8.
    View in: PubMed
    Score: 0.009
  81. Kappe R, Levitz S, Harrison TS, Ruhnke M, Ampel NM, Just-N?bling G. Recent advances in cryptococcosis, candidiasis and coccidioidomycosis complicating HIV infection. Med Mycol. 1998; 36 Suppl 1:207-15.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.